RT Journal Article
T1 European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease.
A1 Bartoletti, Michele
A1 Azap, Ozlem
A1 Barac, Aleksandra
A1 Bussini, Linda
A1 Ergonul, Onder
A1 Krause, Robert
A1 Martin-Quiros, Alejandro
A1 Paño-Pardo, Jose Ramon
A1 Power, Nicholas
A1 Sibani, Marcella
A1 Szabo, Balint Gergely
A1 Tsiodras, Sotirios
A1 Zollner-Schwetz, Ines
A1 Rodriguez-Baño, Jesus
K1 COVID-19
K1 Cilgavimab
K1 ESCMID
K1 Molnupiravir
K1 Nirmatrelvir/ritonavir
K1 Outpatients
K1 Remdesivir
K1 Sotrovimab
K1 Tixagevimab
AB Despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization. A European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. In this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April-June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, constant monitoring of variants of concern is mandatory.
PB Elsevier Ltd
YR 2022
FD 2022-08-24
LK http://hdl.handle.net/10668/22136
UL http://hdl.handle.net/10668/22136
LA en
NO Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al.  European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. Clin Microbiol Infect. 2022 Dec;28(12):1578-1590.
DS RISalud
RD Sep 27, 2025